Drug intelligence / Profile preview

Luprinn

Development stage: Unknown
Lead developer: INNventa Pharm
Administration: Oral

Overview

Luprinn is a dietary supplement developed by INNventa Pharm, specifically formulated to alleviate symptoms associated with menopause, such as hot flashes, night sweats, irritability, and insomnia. The active ingredient in Luprinn is Lifenol, a standardized dry extract of hops (Humulus lupulus) flowers. Lifenol is characterized by its high concentration of 8-prenylnaringenin (8-PN), which is recognized as one of the most potent phytoestrogens. It acts as a natural selective estrogen receptor modulator, helping to compensate for the decline in endogenous estrogen levels during the menopausal transition without the side effects typically associated with synthetic hormone replacement therapy.

Brand names: Luprinn
Other names: LifenolHops extractHumulus lupulus extract

Targets

ESR2 (ERβ)ESR1 (ERα)

Beyond the preview

Go deeper on Luprinn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luprinn.

Explore the full profile